Business NewsPR NewsWire • Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

OSLO, Norway, Dec. 12, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not eligible for autologous stem cell transplantation...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovector-provides-update-on-lymrit-37-05-phase-1-dlbcl-trial-30097...
Releted News by prnewswire
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
Castellum Acquires Properties in Central Västerås